Next Article in Journal
Genetically Encoded Self-Assembling Iron Oxide Nanoparticles as a Possible Platform for Cancer-Cell Tracking
Next Article in Special Issue
Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines
Previous Article in Journal
Liposomes to Augment Dialysis in Preclinical Models: A Structured Review
Previous Article in Special Issue
Hepatocellular-Targeted mRNA Delivery Using Functionalized Selenium Nanoparticles In Vitro
Review

The Ins and Outs of Messenger RNA Electroporation for Physical Gene Delivery in Immune Cell-Based Therapy

1
Tumor Immunology Group, Laboratory of Experimental Hematology, Faculty of Medicine and Health Sciences, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, 2610 Wilrijk, Belgium
2
Center for Cell Therapy & Regenerative Medicine, Antwerp University Hospital, 2650 Edegem, Belgium
3
Division of Hematology, Antwerp University Hospital, 2650 Edegem, Belgium
*
Authors to whom correspondence should be addressed.
Academic Editor: Satoshi Uchida
Pharmaceutics 2021, 13(3), 396; https://doi.org/10.3390/pharmaceutics13030396
Received: 19 January 2021 / Revised: 7 March 2021 / Accepted: 10 March 2021 / Published: 16 March 2021
Messenger RNA (mRNA) electroporation is a powerful tool for transient genetic modification of cells. This non-viral method of genetic engineering has been widely used in immunotherapy. Electroporation allows fine-tuning of transfection protocols for each cell type as well as introduction of multiple protein-coding mRNAs at once. As a pioneering group in mRNA electroporation, in this review, we provide an expert overview of the ins and outs of mRNA electroporation, discussing the different parameters involved in mRNA electroporation as well as the production of research-grade and production and application of clinical-grade mRNA for gene transfer in the context of cell-based immunotherapies. View Full-Text
Keywords: messenger RNA; gene delivery; electroporation; in vitro transcription; immune cell-based therapy messenger RNA; gene delivery; electroporation; in vitro transcription; immune cell-based therapy
Show Figures

Figure 1

MDPI and ACS Style

Campillo-Davo, D.; De Laere, M.; Roex, G.; Versteven, M.; Flumens, D.; Berneman, Z.N.; Van Tendeloo, V.F.I.; Anguille, S.; Lion, E. The Ins and Outs of Messenger RNA Electroporation for Physical Gene Delivery in Immune Cell-Based Therapy. Pharmaceutics 2021, 13, 396. https://doi.org/10.3390/pharmaceutics13030396

AMA Style

Campillo-Davo D, De Laere M, Roex G, Versteven M, Flumens D, Berneman ZN, Van Tendeloo VFI, Anguille S, Lion E. The Ins and Outs of Messenger RNA Electroporation for Physical Gene Delivery in Immune Cell-Based Therapy. Pharmaceutics. 2021; 13(3):396. https://doi.org/10.3390/pharmaceutics13030396

Chicago/Turabian Style

Campillo-Davo, Diana, Maxime De Laere, Gils Roex, Maarten Versteven, Donovan Flumens, Zwi N. Berneman, Viggo F.I. Van Tendeloo, Sébastien Anguille, and Eva Lion. 2021. "The Ins and Outs of Messenger RNA Electroporation for Physical Gene Delivery in Immune Cell-Based Therapy" Pharmaceutics 13, no. 3: 396. https://doi.org/10.3390/pharmaceutics13030396

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop